Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - Case report and review of the literature

Pediatric Transplantation

Volumn 12, Issue 8, 2008, Pages 914-917

  Al Masri, Omar ^a   Fathallah, Waseem ^a   Quader, Suzanne ^a  

^a SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

Author keywords

Brachial neuritis; Calcineurin inhibitor sparing; Everolimus; Myelitis; Neurotoxicity; Pediatric; Renal transplant; Tacrolimus

Indexed keywords

EVEROLIMUS; GABAPENTIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS;

ANAMNESIS; ARTICLE; BRACHIAL PLEXUS; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEURITIS; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHOOL CHILD; TREATMENT OUTCOME;

BRACHIAL PLEXUS NEURITIS; CHILD; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; MALE; SIROLIMUS; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME;

EID: 54849407364     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00961.x     Document Type: Article

References (21)

1. Kari JA, Trumpeter RS. What is the calcineurin inhibitor of choice for pediatric renal transplantation? Pediatr Transplant 2004 : 8 : 437 444.
2. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005 : 19 : CD003961.
3. Harmon W, Meyers K, Ingelfinger J, et al. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006 : 17 : 1735 1745.
4. Venkat KK, Venkat A. Care of the renal transplant recipient in the emergency department. Ann Emerg Med 2004 : 44 : 330 341.
5. Bechstein WO. Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transpl Int 2000 : 13 : 313 326.
6. Fujii N, Ikeda K, Koyama M, et al. Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2006 : 83 : 459 461.
7. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007 : 7 : 560 570.
8. Asberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006 : 15 : 82, 62 68.
9. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005 : 16 : 2234 2240.
10. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004 : 4 : 1776 1785.
11. Yango A, Morrissey P, Monaco A, Butera J, Gohh RY. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clin Nephrol 2002 : 58 : 77 78.
12. Oyen O, Strøm EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006 : 6 : 412 418.
13. Cotterell AH, Fisher RA, King AL, et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002 : 16 (Suppl. 7 49 51.
14. Forgacs B, Merhav HJ, Lappin J, Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005 : 37 : 1912 1914.
15. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005 : 31 : 352, 1317 1323.
16. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006 : 21 : 562 568.
17. Powell HR, Kara T, Jones CL. Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 2007 : 22 : 1773 1777.
18. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004 : 43 : 83 95.
19. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc 2004 : 2 (Suppl. 500S 503S.
20. Ettenger RB, Grimm EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001 : 4 (Suppl. 2 S22 S28.
21. Hoyer PF, Ettenger R, Kovarik JM, et al. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003 : 27 : 75, 2082 2085.